Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07385703, led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 752 participants (estimated). The study started in 2026-04-15 and primary completion is expected in 2028-10. No results have been posted on ClinicalTrials.gov.